D. E. Shaw & Co., Inc. Zynerba Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.5 - $0.72 $186,026 - $267,877	-372,052 Reduced 65.6%	195,064 $103,000
Q3 2022 Nov 14, 2022	SELL	$0.87 - $1.36 $471,573 - $737,173	-542,039 Reduced 48.87%	567,116 $415,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $2.06 $85,763 - $205,433	-99,725 Reduced 8.25%	1,109,155 $1.26 Million
Q1 2022 May 16, 2022	BUY	$1.83 - $3.02 $94,186 - $155,433	51,468 Added 4.45%	1,208,880 $2.48 Million
Q4 2021 Feb 14, 2022	SELL	$2.88 - $4.3 $715,901 - $1.07 Million	-248,577 Reduced 17.68%	1,157,412 $3.33 Million
Q3 2021 Nov 15, 2021	BUY	$3.72 - $5.35 $1.24 Million - $1.78 Million	332,989 Added 31.03%	1,405,989 $5.96 Million
Q2 2021 Aug 16, 2021	BUY	$3.83 - $5.98 $2.93 Million - $4.58 Million	765,962 Added 249.47%	1,073,000 $5.68 Million
Q1 2021 May 17, 2021	BUY	$3.33 - $8.76 $895,370 - $2.36 Million	268,880 Added 704.65%	307,038 $1.43 Million
Q4 2020 Feb 16, 2021	BUY	$3.27 - $4.64 $124,776 - $177,053	38,158 New	38,158 $126,000
Q4 2017 Feb 14, 2018	SELL	$8.69 - $14.59 $260,673 - $437,656	-29,997 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.73 - $9.44 $171,882 - $283,171	29,997	29,997 $251,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.